The Competition Commission has ordered a probe against Max Super Speciality Hospital and medical technology company Becton Dickinson India for alleged anti-competitive practices with respect to healthcare services.
The watchdog found a prima facie case of contravention of provisions of Section 4 of the Act by the two parties and has directed its investigation arm Director General (DG) to complete the investigation within a period of 60 days.
According to the complaint filed by the informant Vivek Sharma, the two parties charged a higher MRP for disposable syringe manufactured by Becton Dickinson India and brought from an in-house pharmacy located within the hospital network of Max Super Speciality Hospital.
Becton Dickinson manufactures disposable syringe under the brand name ‘Emerald’, while Max Super Speciality Hospital is a leading multi-speciality hospital in Patparganj, New Delhi.
The CCI considered ‘provision of healthcare services by super speciality hospitals in Delhi’ as the relevant market in this case.